Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TAVR Registry Data Triggers Expansion Of FDA-Approved Indication

This article was originally published in The Gray Sheet

Executive Summary

FDA has changed the indication for transcatheter aortic valves to include any access approach for inoperable patients. The new indication, based largely on registry data, is significant due to the “message that FDA is sending in that they are looking at ways of post-market surveillance,” said surgeon Michael Mack.

Advertisement

Related Content

AdvaMed Emphasizes Threshold Questions, Data Governance In Registry Principles
Early Registry Outcomes Suggest TAVR Roll-Out Has Been Successful So Far
FDA Convenes Industry, Physicians To Create International Transcatheter Valve Registry Consortium
Societies Gain FDA Go-Ahead, Medicare Coverage To Study New Access Methods For Edward’s Sapien Valve
CMS Policy Sets Boundaries On Transcatheter Valve Procedure

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT032450

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel